Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia. Disease ...

Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative ... olivopontocerebellar atrophy and Shy-Drager syndrome. MSA is considered a rare disease affecting potentially 15,000 ...

which has more parkinsonian symptoms but is relatively unresponsive to the usual therapy for Parkinson’s disease (i.e., levodopa). Some of the atypical parkinsonian disorders, such as progressive ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity ...

Patients with iRBD showed decreased GMV in the prefrontal cortices, temporal lobe, and caudate, and increased cerebellar and thalamic GMV.

Given that alpha-synuclein pathology is also observed in a range of related diseases, such as multiple systems atrophy and some forms of Alzheimer's disease, the results from this study are far ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Sharon Kay Morgan Sharon Morgan passed away on 12/05/2024, surrounded by family, due to effects of Multiple Systems Atrophy (MSA), an atypical Parkinson’s disease. Sharon was born on 01/27/1943 ...

The severity and progression of the disease was evaluated by the Unified MSA Rating Scale (UMSARS), a validated and disease-specific instrument. [17] UMSARS part I (UMSARS-I) evaluates activities ...